Product Overview

Bromocriptine 1.25 mg (Generic) is a prescription oral tablet produced by Serum Institute India. Each strip contains ten tablets, and the product is marketed in pack sizes of 30, 60, or 90 tablets to accommodate different treatment durations. The active ingredient, bromocriptine mesylate, is a synthetic ergot derivative that functions primarily as a dopamine‑D2 receptor agonist. Clinically, it is used to lower elevated prolactin levels, to restore normal ovarian function in women with hyperprolactinemic infertility, and to provide modest improvements in glycemic control when used as an adjunct in type 2 diabetes mellitus. The medication is supplied in a blister pack that protects the tablets from moisture and light, ensuring stability throughout the shelf life. All batches are manufactured under strict Good Manufacturing Practice (GMP) standards and are accompanied by a certificate of analysis that confirms identity, potency, and purity.

What is Bromocriptine 1.25 mg (Generic)

Bromocriptine belongs to the pharmacological class of ergot alkaloids and is chemically designated as (R)-N‑[2‑hydroxy‑1‑(phenyl‑ethyl)‑ethyl]‑2‑methoxy‑N‑phenyl‑2‑propyl‑amine. Its primary therapeutic action is mediated through stimulation of dopamine D2 receptors located in the tuberoinfundibular pathway of the hypothalamus. Activation of these receptors inhibits the release of prolactin from lactotroph cells of the anterior pituitary, resulting in a dose‑dependent reduction of serum prolactin concentrations. In addition to its endocrine effects, bromocriptine influences central nervous system pathways that regulate appetite, metabolism, and glucose homeostasis. The 1.25 mg strength is the standard dose employed for the treatment of hyperprolactinemia and associated reproductive disorders, while lower or higher doses are generally reserved for research settings or specific clinical protocols.

For an in‑depth chemical description, consult the National Institutes of Health’s PubChem entry for bromocriptine, accessible at PubChem.

Uses and Benefits

The therapeutic applications of bromocriptine 1.25 mg are broad and include:

• Hyperprolactinemia Management: Reduction of excessive prolactin levels can restore normal menstrual cycles, improve ovulatory function, and increase the probability of conception in women with idiopathic or pituitary‑related hyperprolactinemia.
• Female Infertility Treatment: Clinical studies indexed in PubMed have demonstrated that bromocriptine therapy can raise pregnancy rates by up to 30 % in appropriately selected patients when combined with timed intercourse or assisted reproductive techniques.
• Adjunct in Type 2 Diabetes: When used as an add‑on to standard antidiabetic agents, bromocriptine may contribute to modest reductions in fasting plasma glucose and glycated hemoglobin (HbA1c), particularly in patients who also present with hyperprolactinemia.
• Long‑Term Oral Administration: The tablet formulation allows for once‑daily dosing, which improves adherence compared with injectable or multi‑dose regimens.
• Well‑Tolerated Profile: At the 1.25 mg dose, the incidence of severe adverse events is low, making it suitable for chronic therapy under medical supervision.

Evidence supporting these uses is documented in systematic reviews published by the Cochrane Library and in clinical practice guidelines from the Endocrine Society, both of which reference peer‑reviewed trials and meta‑analyses.

How It Works

The pharmacological mechanism of bromocriptine centers on its high affinity for dopamine D2 receptors in the hypothalamus. By occupying these receptors, bromocriptine suppresses the activity of lactotroph cells, thereby decreasing prolactin secretion from the pituitary gland. This reduction in prolactin can reverse the negative feedback loop that often inhibits gonadotropin‑releasing hormone (GnRH) release, leading to the restoration of normal follicular development and ovulation. In the context of diabetes, bromocriptine appears to modulate central pathways that influence insulin secretion and peripheral insulin sensitivity, although the exact magnitude of this effect at the 1.25 mg dose remains modest and is considered supplementary to primary glucose‑lowering agents.

Pharmacokinetic data indicate that bromocriptine is rapidly absorbed after oral administration, with peak plasma concentrations occurring within one to two hours. The drug undergoes extensive first‑pass metabolism, primarily via the hepatic enzyme CYP3A4, and is eliminated renally. Detailed pharmacokinetic parameters are available through the FDA’s drug database, which can be accessed at FDA Drug Approvals and Databases.

Dosage Guidelines

Dosage of bromocriptine 1.25 mg must be individualized by the prescribing clinician based on the patient’s clinical response, baseline prolactin levels, and tolerability. Typical initial regimens are outlined below:

• For hyperprolactinemia in adult women: 1.25 mg taken once daily, with titration up to 2.5 mg per day if needed after four to six weeks of therapy, provided serum prolactin declines by at least 50 % without significant adverse effects.
• For adjunct treatment of type 2 diabetes: 2.5 mg taken once daily in the morning, often combined with metformin or a sulfonylurea, with dose adjustments made according to glycemic response.

If a dose is missed, the patient should take it as soon as remembered unless it is near the time of the next scheduled dose; in that case, the missed dose should be skipped and therapy resumed at the regular interval. Overdose is uncommon but may present with nausea, vomiting, and hypotension; medical attention should be sought immediately if an overdose is suspected.

Patients are advised to undergo periodic laboratory monitoring, including serum prolactin, liver function tests, and fasting glucose, to evaluate treatment efficacy and detect any emerging safety signals. Real‑world dosing experiences are summarized in prescribing information available on Drugs.com.

Side Effects

Adverse reactions to bromocriptine 1.25 mg are generally mild to moderate and often diminish with continued therapy. The most commonly reported side effects include:

• Gastrointestinal discomfort such as nausea, vomiting, or abdominal cramping.
• Headache, dizziness, or mild vertigo, particularly during the first few days of treatment.
• Transient drops in blood pressure when standing (orthostatic hypotension).
• Fatigue or difficulty sleeping (insomnia).
• Rare occurrences of skin rash, itching, or mild allergic reactions.

Although the low dose of 1.25 mg carries a minimal risk of valvular heart disease—a concern historically associated with higher‑dose ergot derivatives—patients with pre‑existing cardiac conditions should be monitored closely. If severe chest pain, shortness of breath, or signs of a serious hypersensitivity reaction develop, immediate medical evaluation is required.

Long‑term safety data from registries and post‑marketing surveillance suggest that the incidence of serious cardiovascular events remains low at the therapeutic dose, but ongoing vigilance is recommended, especially in elderly patients or those on concomitant cardiovascular medications.

Warnings and Precautions

Before initiating bromocriptine therapy, healthcare providers should assess the following considerations:

• Cardiovascular History: Patients with a history of valvular heart disease, hypertension, or recent myocardial infarction should be evaluated carefully, as ergot alkaloids can theoretically exacerbate these conditions.
• Pregnancy and Lactation: Bromocriptine is classified as pregnancy category C. Its use during pregnancy should be justified only when the expected benefit outweighs potential fetal risk, and breastfeeding is generally discouraged while taking the medication.
• Drug Interactions: Concomitant use with other dopamine‑modulating agents (e.g., antipsychotics, metoclopramide) may alter bromocriptine’s efficacy or increase side‑effect frequency. Additionally, inhibitors or inducers of CYP3A4 enzymes can affect bromocriptine plasma levels, necessitating dose adjustments.
• Renal or Hepatic Impairment: Patients with significant renal or hepatic dysfunction may require dose reduction, as bromocriptine is primarily cleared renally and metabolized hepatically.
• Orthostatic Hypotension: Initiating therapy with a lower dose and gradually titrating upward can mitigate the risk of blood pressure drops.

Patients should be instructed to report any new or worsening symptoms to their physician promptly. For comprehensive safety information, refer to the NIH’s MedlinePlus drug entry at MedlinePlus.

Patient Counseling

Healthcare professionals should provide clear instructions to patients regarding proper use of bromocriptine 1.25 mg:

• Take the tablet with food to reduce gastrointestinal upset.
• Do not crush or chew the tablet; swallow it whole.
• Maintain a consistent daily dosing schedule to achieve steady plasma concentrations.
• Store the medication at room temperature, away from moisture and heat.
• Keep a medication list and share it with all healthcare providers to avoid harmful interactions.

Patients should be reminded that bromocriptine is part of a broader treatment plan that may include lifestyle modifications, fertility counseling, or additional antidiabetic agents, depending on the underlying condition.

Conclusion

Bromocriptine 1.25 mg (Generic) offers a targeted therapeutic option for women experiencing infertility due to elevated prolactin and for patients with type 2 diabetes who require additional glycemic control. Its proven efficacy, supported by clinical research and endorsed by reputable endocrine societies, combined with a manageable safety profile, makes it a valuable component of comprehensive disease management. Patients are encouraged to work closely with their healthcare provider to determine the appropriate dose, monitor response, and address any concerns throughout the course of treatment.

Frequently Asked Questions

1. Q: What condition does bromocriptine 1.25 mg treat?
   A: It is indicated for hyperprolactinemia, female infertility related to elevated prolactin, and as an adjunct in type 2 diabetes management.
2. Q: How should I store the tablets?
   A: Keep the strip at room temperature, away from moisture and direct sunlight, and out of reach of children.
3. Q: Can I take bromocriptine with other diabetes medications?
   A: Yes, but only under medical supervision; dose adjustments may be needed to prevent hypoglycemia.
4. Q: Is a prescription required to purchase bromocriptine online?
   A: Yes, a valid prescription from a licensed healthcare provider is required before dispensing the medication.
5. Q: How long does it take to see improvements in prolactin levels?
   A: Most patients experience a reduction in serum prolactin within 2–4 weeks of consistent daily dosing, though individual response may vary.

For additional information on bromocriptine, consult authoritative sources such as the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and Drugs.com.

Related Products

• CB-Lin (Cabergoline)
• Meprate 10 mg (Medroxyprogesterone)
• Sicriptin 2.5 mg Tablets (Bromocriptine)
• Sicriptin 1.25 mg Tablets (Bromocriptine)
• Sicriptin (Bromocriptine)
• Bromocriptine 2.5 mg (Generic)
• Sifasi Aqua 5000 (HCG (Human Chorionic Gonadotropin))
• Clomiphene 25 mg (Generic)
• Siphene 100 mg (Clomiphene)
• Siphene 50 mg (Clomiphene)
• Siphene M 25 mg (Clomiphene)
• Siphene (Clomiphene)